Markets
ABT

Abbott Laboratories Gains Despite Unimpressive Q4 Revenue Results

An image of people surrounding a sheet of paper with many charts on it
Credit: Shutterstock photo

Abbott Laboratories ABT just released its fourth quarter fiscal 2016 earnings results, posting earnings of $0.65 per share and revenue of $5.33 billion.

ABT closed at a gain of $0.56 to $40.32 a shareafter its earnings report was released this morning.

Currently, ABT has a Zacks Rank #3 (Hold), but it is subject to change following the release of the company's latest earnings report. Here are 5 key statistics from this just announced report below.

Company:

Beat earnings estimates. The company posted earnings of $0.65 cents per share, beating our Zacks Consensus Estimate of $0.64. Zacks estimates excluded $0.12 from non-recurring items.

Underperformed revenue estimates. The company saw revenue figures of $5.33 billion, not meeting our estimate of $5.357 billion.

Abbott Laboratories reported that in their fourth quarter Pediatric Nutrition sales decreased by 5.4% and worldwide Adult Nutrition sales fell 1.4%, on a reported basis. However, Abbott's PediaSure brand and other recently launched infant formula products led above-market sales growth in the United States.

Diluted GAAP EPS from continuing operations shows an outlook for full-year 2017 to be between $0.92 and $1.02 a share. This guidance includes amortization and integration expenses to the acquisition of St. Jude Medical.

Good news for investors, as Abbott Laboratories will continue to increase its quarterly dividend payment by $0.005 to $0.0265.

Here's a graph that looks at Abbott Laboratories' price, consensus and EPS surprise:

Abbott Laboratories Price, Consensus and EPS Surprise

Abbott Laboratories participates in the sale of health care products through their own discoveries, developments and manufacturing. The company employees 74,000 employees around the world and can be found in over 150 countries. Products in the categories of nutrition, diagnostics, diabetes care and pharmaceuticals are sold by them.

Zacks' Top Investment Ideas for Long-Term Profit

How would you like to see our best recommendations to help you find today's most promising long-term stocks? Starting now, you can look inside our portfolios featuring stocks under $10, income stocks, value investments and more. These picks, which have double and triple-digit profit potential, are rarely available to the public. But you can see them now. Click here >>

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

Abbott Laboratories (ABT): Free Stock Analysis Report

To read this article on Zacks.com click here.

Zacks Investment Research

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.


The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

In This Story

ABT

Other Topics

Stocks

Latest Markets Videos

    Zacks

    Zacks is the leading investment research firm focusing on stock research, analysis and recommendations. In 1978, our founder discovered the power of earnings estimate revisions to enable profitable investment decisions. Today, that discovery is still the heart of the Zacks Rank. A wealth of resources for individual investors is available at www.zacks.com.

    Learn More